Presented by Benjamin Kitchens, MD; Rachna Shroff, MD, MS, FASCO; Nilofer Azad, MD, FASCO; and Tanios Bekaii-Saab, MD

Join Drs. Kitchens, Shroff, Azad, and Bekaii-Saab as they explore the evolving treatment landscape of advanced biliary tract cancer.

• Dr. Kitchens provides an overview of the new 4-year data from the TOPAZ-1 trial. Dr. Shroff reviews a real-world case of a patient with advanced intrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin plus durvalumab.
• Dr. Azad explores how various patient characteristics affect outcomes on first-line therapy.
• Finally, Dr. Bekaii-Saab presents the case of disease progression on first-line therapy in the presence of FGFR fusion.
  
  

Benjamin Kitchens, MD, is a board-certified medical oncologist with Texas Oncology in Dallas, Texas. Rachna Shroff, MD, MS, FASCO, is Chief, Division of Hematology/Oncology, Professor of Medicine at University of Arizona Comprehensive Cancer Center in Phoenix, Arizona. Nilofer Azad, MD, FASCO, is Associate Director of Clinical Research, Sidney Kimmel Cancer Center at Johns Hopkins University in Baltimore, Maryland. Tanios Bekaii-Saab, MD, is Division Chair, Division of Hematology and Medical Oncology at Mayo Clinic in Phoenix, Arizona.